Niagen Bioscience (NAGE) Receivables (2011 - 2026)

Niagen Bioscience (NAGE) has 16 years of Receivables data on file, last reported at $13.1 million in Q1 2026.

• Receivables for Q1 2026 came in at $13.1 million, up 85.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.1 million (up 85.76% YoY), and the FY2025 annual result was $9.7 million, up 25.4% from the prior year.
• Receivables grew to $13.1 million in Q1 2026 per NAGE's latest filing, from $9.7 million in the prior quarter.
• Over five years, Receivables peaked at $13.1 million in Q1 2026 and troughed at $2.8 million in Q2 2023.
• A 5-year average of $7.4 million and a median of $7.1 million in 2022 frame the typical range for Receivables.
• The sharpest annual moves came in 2023 and 2024: Receivables plunged 59.41% in 2023, then surged 179.21% in 2024.
• A 5-year view of Receivables shows it stood at $6.2 million in 2022, then plunged by 54.84% to $2.8 million in 2023, then soared by 177.43% to $7.8 million in 2024, then advanced by 25.4% to $9.7 million in 2025, then surged by 34.48% to $13.1 million in 2026.
• Business Quant data shows NAGE's Receivables at $13.1 million in Q1 2026, $9.7 million in Q4 2025, and $8.5 million in Q3 2025.